Product Manager's Handbook - Pharmaceutical Executive

ADVERTISEMENT

Product Manager's Handbook

Key Opinion Leaders Interactions with Pharma

October 1, 2005

Data suggest that pharma companies engage the same key opinion leaders on assignments in three to seven departments or product groups at once.

Sampling: Crimes in the Closet

October 1, 2005

The pharmaceutical industry devotes more of its promotional budget to samples than anything else, unless you count the army of sales representatives that delivers them. This year, the average wholesale price of samples passed out to doctors will approach $15 billion—roughly twice the value of samples five years ago. And although few in the industry have come to grips with it, the federal regulations governing this enormous investment have undergone drastic changes.

Formulary Additions: The Big Picture

October 1, 2005

To get along with the CFO, drug companies need to express more data in units that a health plan can integrate into its own internal actuarial analysis. The financial decision makers at a health plan want to know how a new drug affects the value of expected claims on the whole.

From the Editor: Incorporating Compliance

October 1, 2005

Think of the role compliance plays in your job. Now imagine that level of concern increased by 25 percent, 50, or even more. That's what pharma has to look forward to in the next few years, as the effects of old regulatory initiatives, such as 21 CFR Part 11 and Sarbanes Oxley, start fully kicking in—and as we experience the as-yet-unknown regulatory fallout of the new concern with drug safety. It's no surprise that a great portion of this volume of Pharm Exec's Successful Product Manager's Handbook series is given over to compliance.

Physician Frustration

October 1, 2005

As the industry thinks about new sales force models, it should look beyond ROI numbers, toward a new paradigm that not only works for pharma, but also for its customers.

Orchestrating Compliance

October 1, 2005

Product managers would be less disrupted if compliance activities at pharma companies were more anticipatory than reactionary.

Ad Agencies to the Rescue

October 1, 2005

The client-agency relationship is a product of its environment. Chock-full of regulatory requirements, scandals, and heightened FDA scrutiny, the current environment leaves much to be desired. But this is hardly news for the pharma industry.

ADVERTISEMENT

Click here